Skye Bioscience to Present Poster on Nimacimab at Keystone Obesity Conference

Skye Bioscience will present a poster at Keystone's Obesity Therapeutics conference, addressing questions about its peripherally-restricted CB1-inhibitor antibody, nimacimab. The poster will explore its potential to enhance weight loss with incretin agonists, durability of weight loss after treatment discontinuation, and use as a maintenance therapy after tirzepatide discontinuation. Nimacimab is a potential first-in-class drug designed to avoid central nervous system penetration and act independently of the GLP-1 pathway.